Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts
Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken
At the time of publication, Cramer was long ___.
At the time of publication, Cramer was long ___.
